Compare RETO & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RETO | MBAI |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | China | Israel |
| Employees | N/A | 85 |
| Industry | Multi-Sector Companies | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 10.3M |
| IPO Year | 2016 | N/A |
| Metric | RETO | MBAI |
|---|---|---|
| Price | $2.68 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 52.9K | ★ 62.3K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $1.06 |
| 52 Week High | $4.66 | $3.92 |
| Indicator | RETO | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 58.54 | 36.46 |
| Support Level | $2.49 | N/A |
| Resistance Level | $2.80 | $2.02 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 59.32 | 20.17 |
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Equipment and technical service segment, and Craft beer segment. The company earns its revenue from the Equipment and technical service segment. Geographically, it derives a majority of its revenue from China.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.